OKUR OnKure Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1637715 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY2.5%
TTM EPS YoY-102.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-55.2%
ROA-51.6%
ROIC (approx.)-4,360.7%
Asset turnover—
Leverage & solvency
Liabilities / assets5.6%
Debt / equity0.00x
Current ratio18.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $0 | — | — | — |
| R&D expense | $48.26M | $43.80M | $32.12M | $37.70M | $28.17M |
| SG&A expense | $14.69M | $10.59M | $4.82M | $16.14M | $11.65M |
| Operating income | -$62.95M | -$54.39M | -$36.93M | -$53.85M | -$39.82M |
| Pretax income | — | — | -$77.39M | -$51.95M | -$39.77M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.52M | -$52.67M | -$35.31M | -$51.95M | -$39.77M |
| EBITDA | -$62.50M | -$53.93M | -$36.52M | -$53.76M | -$39.77M |
| EPS (basic) | -4.40 | -15.28 | -124.41 | -2.12 | -2.19 |
| EPS (diluted) | -4.40 | -15.28 | -124.41 | -2.12 | -2.19 |
| Weighted avg. shares (diluted) | 13.52M | 3.45M | 283,817 | 24.50M | 18.14M |
| Banking | |||||
| Net interest income | $3.43M | $1.71M | $1.62M | — | — |
| Balance sheet | |||||
| Cash & equivalents | $59.05M | $110.76M | $29.88M | $11.54M | $124.66M |
| Short-term investments | $0 | — | $75.33M | $81.25M | $23.01M |
| Current assets | $60.84M | $113.00M | $33.77M | $106.35M | $153.73M |
| PP&E, net | $618,000 | $1.02M | $1.43M | $453,000 | $212,000 |
| Total assets | $62.12M | $114.91M | $35.73M | $108.18M | $154.02M |
| Current liabilities | $5.92M | $10.53M | $7.29M | $7.12M | $6.20M |
| Total liabilities | $5.93M | $11.08M | $7.75M | $8.21M | $6.81M |
| Shareholders' equity | $56.18M | $103.83M | -$101.84M | -$54.42M | $147.21M |
| Shares outstanding | — | — | 3.34M | 24.70M | 24.46M |
| Cash flow statement | |||||
| Operating cash flow | -$51.83M | -$51.12M | -$34.55M | -$47.36M | -$37.98M |
| Capital expenditure | $46,000 | $52,000 | $246,000 | $346,000 | $198,000 |
| Free cash flow | -$51.87M | -$51.17M | -$34.79M | -$47.71M | -$38.18M |
| Investing cash flow | -$46,000 | $15.87M | -$246,000 | -$57.84M | -$23.38M |
| Financing cash flow | $163,000 | $116.13M | $53.12M | $471,000 | $132.41M |
| Depreciation & amortization | $447,000 | $459,000 | $417,000 | $88,000 | $50,000 |
| Stock-based compensation | $11.63M | $4.53M | $199,000 | $4.32M | $3.89M |
| Share buybacks | — | — | $4.40M | — | — |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.